Lilly’s GLP-1 Pill Outperforms Older Novo Drug

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on “Bloomberg Open Interest.”...

Redirecting to full article...